Skip to main content
x

Recent articles

Rakuten sheds light on its conjugate

The company secures funding to push its lead candidate towards US approval.

CG Oncology gets an intermediate-risk bladder boost

Readout of the Pivot-006 trial is brought forward by nearly a year.

Eikon tries to follow Aktis

After Aktis's $318m flotation Eikon is a bigger proposition.

AbbVie is next to the VEGF bispecific table

$650m buys the group rights to RemeGen’s RC148.

ASCO-GI – Astellas focuses on a degrader-chemo combo

A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.

Different dosing enlivens Enliven’s share price

ELVN-001 is made to look more like Terns’ TERN-701.